(Q34190116)

31 July 2017

1 reference

MDMA

0 references

title

A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA (English)

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

post-traumatic stress disorder

23 December 2023

main subject

0 references

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

23 December 2023

author name string

Rick Doblin

1

1 reference

PubMed ID

12691208

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

12691208

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12691208

23 December 2023

publication date

1 April 2002

1 reference

Journal of Psychoactive Drugs

31 July 2017

1 reference

31 July 2017

34

1 reference

31 July 2017

185-194

1 reference

31 July 2017

2

1 reference

The relative contributions of ecstasy and cannabis to cognitive impairment

31 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Low-dose MDMA ("ecstasy") induces vasopressin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

The subjective effects of MDMA and mCPP in moderate MDMA users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02791072.2002.10399952

Memory impairment in abstinent MDMA ("Ecstasy") users.

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

23 December 2023

9

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations

23 December 2023

14

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS

23 December 2023

16

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Power to detect differences between alternative treatments in comparative psychotherapy outcome research.

23 December 2023

21

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Caveat emptor: researcher beware

23 December 2023

23

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat.

23 December 2023

25

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Journal of Pharmacology and Experimental Therapeutics

23 December 2023

26

278

258

Malberg J.

1996

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Journal of Pharmacology and Experimental Therapeutics

23 December 2023

27

290

136

Mas M.

1999

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study

23 December 2023

37

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

Is a single dose of MDMA harmless?

23 December 2023

46

1 reference

https://api.crossref.org/works/10.1080/02791072.2002.10399952

23 December 2023

Identifiers

1 reference

31 July 2017

1 reference

PubMed ID

12691208